Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?

Hennigs A, Köpke M, Feißt M, Riedel F, Rezai M, Nitz U, Moderow M, Golatta M, Sohn C, Schneeweiss A, Heil J.

Breast Cancer Res Treat. 2018 Oct 12. doi: 10.1007/s10549-018-5009-2. [Epub ahead of print]

PMID:
30315437
2.

Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.

Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Bangemann N, Lindner C, Kuemmel S, Clemens M, Potenberg J, Staib P, Kohls A, von Schumann R, Kates R, Kates R, Schumacher J, Wuerstlein R, Kreipe HH, Harbeck N.

J Natl Cancer Inst. 2018 Jun 1;110(6):628-637. doi: 10.1093/jnci/djx258.

PMID:
29228315
3.

Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.

Möbus V, Jackisch C, Lück HJ, du Bois A, Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Konecny GE, Untch M, Kurbacher C; AGO Breast Study Group (AGO-B).

Ann Oncol. 2018 Jan 1;29(1):178-185. doi: 10.1093/annonc/mdx690.

PMID:
29069370
4.

Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β.

Raap M, Gronewold M, Christgen H, Glage S, Bentires-Alj M, Koren S, Derksen PW, Boelens M, Jonkers J, Lehmann U, Feuerhake F, Kuehnle E, Gluz O, Kates R, Nitz U, Harbeck N, Kreipe HH, Christgen M.

Lab Invest. 2018 Jan;98(1):117-129. doi: 10.1038/labinvest.2017.106. Epub 2017 Oct 16.

PMID:
29035379
5.

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.

Nitz UA, Gluz O, Christgen M, Grischke EM, Augustin D, Kuemmel S, Braun M, Potenberg J, Kohls A, Krauss K, Stefek A, Schumacher C, Forstbauer H, Reimer T, Fischer H, Liedtke C, Wuerstlein R, Schumacher J, Kates R, Kreipe H, Harbeck N; West-German Study Group (WSG)-ADAPT Investigators.

Ann Oncol. 2017 Nov 1;28(11):2768-2772. doi: 10.1093/annonc/mdx494.

PMID:
28945833
6.

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.

Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, Schumacher C, Potenberg J, Kraemer S, Kleine-Tebbe A, Augustin D, Aktas B, Forstbauer H, Tio J, von Schumann R, Liedtke C, Grischke EM, Schumacher J, Wuerstlein R, Kreipe HH, Nitz UA.

J Clin Oncol. 2017 Sep 10;35(26):3046-3054. doi: 10.1200/JCO.2016.71.9815. Epub 2017 Jul 6.

PMID:
28682681
7.

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.

Nitz U, Gluz O, Christgen M, Kates RE, Clemens M, Malter W, Nuding B, Aktas B, Kuemmel S, Reimer T, Stefek A, Lorenz-Salehi F, Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, Harbeck N.

Breast Cancer Res Treat. 2017 Oct;165(3):573-583. doi: 10.1007/s10549-017-4358-6. Epub 2017 Jun 29.

PMID:
28664507
8.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2017 Nov 1;28(11):2899. doi: 10.1093/annonc/mdw349. No abstract available.

PMID:
27634692
9.

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators.

N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.

10.

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.

Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH, Hartmann A, Pelz E, Erber R, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Harbeck N; EC-Doc investigators (West German Study Group/AGO-B).

Ann Oncol. 2016 Jun;27(6):1035-40. doi: 10.1093/annonc/mdw070. Epub 2016 Feb 18.

PMID:
27022068
11.

BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.

Schouten PC, Gluz O, Harbeck N, Mohrmann S, Diallo-Danebrock R, Pelz E, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Liedtke C, Frick M, Kates R, Linn SC, Nitz U, Marme F.

Int J Cancer. 2016 Aug 15;139(4):882-9. doi: 10.1002/ijc.30078. Epub 2016 May 5.

12.

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T, Kusche M, Heyl V, Lorenz-Salehi F, Just M, Hofmann D, Degenhardt T, Liedtke C, Svedman C, Wuerstlein R, Kreipe HH, Harbeck N.

J Clin Oncol. 2016 Jul 10;34(20):2341-9. doi: 10.1200/JCO.2015.63.5383. Epub 2016 Feb 29.

PMID:
26926676
13.

Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade.

Müller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K, Savic S, Harbeck N, Nitz U, Gluz O, von Bergwelt-Baildon M, Kreipe H, Reddy S, Christgen M, Zippelius A.

Sci Transl Med. 2015 Nov 25;7(315):315ra188. doi: 10.1126/scitranslmed.aac4925.

PMID:
26606967
14.

Reply to letter to the editor 'Primum non nocere' by Templeton and Šeruga.

Aapro M, Moebus V, Nitz U, O'Shaughnessy J, Pronzato P, Untch M, Tomita D, Bohac C, Leyland-Jones B.

Ann Oncol. 2015 Oct;26(10):2198-9. doi: 10.1093/annonc/mdv294. Epub 2015 Jul 7. No abstract available.

PMID:
26153497
15.

Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.

Erber R, Gluz O, Brünner N, Kreipe HH, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Moustafa Z, Liedtke C, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Hartmann A.

Breast Cancer Res Treat. 2015 Apr;150(2):279-88. doi: 10.1007/s10549-015-3310-x. Epub 2015 Feb 28.

PMID:
25721604
16.

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis.

Aapro M, Moebus V, Nitz U, O'Shaughnessy J, Pronzato P, Untch M, Tomita D, Bohac C, Leyland-Jones B.

Ann Oncol. 2015 Apr;26(4):688-95. doi: 10.1093/annonc/mdu579. Epub 2014 Dec 26.

PMID:
25542926
17.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186. Epub 2014 May 14. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2899.

PMID:
24827128
18.

Response.

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz UA, Runnebaum IB, Hinke A, Kreienberg R, Untch M; AGO Breast Study Group.

J Natl Cancer Inst. 2014 Mar;106(3):djt452. doi: 10.1093/jnci/djt452. Epub 2014 Feb 28. No abstract available.

PMID:
24586093
19.

Genomic profiling in luminal breast cancer.

Gluz O, Hofmann D, Würstlein R, Liedtke C, Nitz U, Harbeck N.

Breast Care (Basel). 2013 Dec;8(6):414-22. doi: 10.1159/000357535. Review.

20.

Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.

Harbeck N, Blettner M, Hadji P, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Haidinger R, Schmitt D, Schulte H, Nitz U, Kreienberg R.

Breast Care (Basel). 2013 May;8(2):110-20. doi: 10.1159/000350777.

21.

Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers.

Rom J, Schumacher C, Gluz O, Höfler J, Eidt S, Domschke C, Marmé F, Nitz U, Sohn C, Schneeweiss A.

Breast Care (Basel). 2013 Jun;8(3):208-14. doi: 10.1159/000352094.

22.

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer.

Nitz U, Gluz O, Zuna I, Oberhoff C, Reimer T, Schumacher C, Hackmann J, Warm M, Uleer C, Runde V, Dünnebacke J, Belzl N, Augustin D, Kates RE, Harbeck N; West German Study Group.

Ann Oncol. 2014 Jan;25(1):75-80. doi: 10.1093/annonc/mdt505.

PMID:
24356620
23.

Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients.

Fischer JC, Niederacher D, Topp SA, Honisch E, Schumacher S, Schmitz N, Zacarias Föhrding L, Vay C, Hoffmann I, Kasprowicz NS, Hepp PG, Mohrmann S, Nitz U, Stresemann A, Krahn T, Henze T, Griebsch E, Raba K, Rox JM, Wenzel F, Sproll C, Janni W, Fehm T, Klein CA, Knoefel WT, Stoecklein NH.

Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16580-5. doi: 10.1073/pnas.1313594110. Epub 2013 Sep 24.

25.

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; AGO Breast Study Group.

J Natl Cancer Inst. 2013 Jul 17;105(14):1018-26. doi: 10.1093/jnci/djt145. Epub 2013 Jul 16.

26.

Recognition and handling of discordant negative human epidermal growth factor receptor 2 classification by Oncotype DX in patients with breast cancer.

Christgen M, Harbeck N, Gluz O, Nitz U, Kreipe HH.

J Clin Oncol. 2012 Sep 10;30(26):3313-4; author reply 3314-5. doi: 10.1200/JCO.2012.42.1990. Epub 2012 May 29. No abstract available.

PMID:
22649153
27.

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.

Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F.

Eur J Cancer. 2011 Dec;47(18):2742-9. doi: 10.1016/j.ejca.2011.09.016. Epub 2011 Nov 1.

PMID:
22051734
28.

High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials.

Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T.

J Clin Oncol. 2011 Aug 20;29(24):3214-23. doi: 10.1200/JCO.2010.32.5910. Epub 2011 Jul 18.

29.

Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

Schmitt M, Harbeck N, Brünner N, Jänicke F, Meisner C, Mühlenweg B, Jansen H, Dorn J, Nitz U, Kantelhardt EJ, Thomssen C.

Expert Rev Mol Diagn. 2011 Jul;11(6):617-34. doi: 10.1586/erm.11.47. Review.

PMID:
21745015
30.

Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.

Gluz O, Wild P, Liedtke C, Kates R, Mendrik H, Ehm E, Artinger V, Diallo-Danebrock R, Ting E, Mohrmann S, Poremba C, Harbeck N, Nitz U, Hartmann A, Gaumann A.

Breast Cancer Res Treat. 2011 Apr;126(3):643-51. doi: 10.1007/s10549-011-1377-6. Epub 2011 Feb 12.

PMID:
21318601
31.

Perspectives: Other ErbB2-Targeted Therapies.

Nitz U.

Breast Care (Basel). 2010;5(s1):25-27. Epub 2010 Apr 26.

32.

Trastuzumab single-drug therapy after failure of cytotoxic treatment for metastatic breast cancer.

Clemens M, Eidtmann H, Nitz U, Niederle N, du Bois A, Grischke EM, Hinke A, von Minckwitz G.

Onkologie. 2010;33(8-9):425-30. doi: 10.1159/000318144. Epub 2010 Jul 27.

PMID:
20838057
33.

Personalized treatment of early-stage breast cancer: present concepts and future directions.

Harbeck N, Salem M, Nitz U, Gluz O, Liedtke C.

Cancer Treat Rev. 2010 Dec;36(8):584-94. doi: 10.1016/j.ctrv.2010.04.007. Epub 2010 Jun 2. Review.

PMID:
20554119
34.

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, von Minckwitz G, Runnebaum IB, Hinke A, Kreienberg R, Konecny GE, Untch M.

J Clin Oncol. 2010 Jun 10;28(17):2874-80. doi: 10.1200/JCO.2009.24.7643. Epub 2010 May 10.

PMID:
20458045
35.

Clinical Recommendations of DEGRO and AGO on Preferred Standard Palliative Radiotherapy of Bone and Cerebral Metastases, Metastatic Spinal Cord Compression, and Leptomeningeal Carcinomatosis in Breast Cancer.

Souchon R, Feyer P, Thomssen C, Fehm T, Diel I, Nitz U, Janni W, Bischoff J, Sauer R.

Breast Care (Basel). 2010 Dec;5(6):401-7. doi: 10.1159/000322661. Review.

36.

Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy.

Gluz O, Mengele K, Schmitt M, Kates R, Diallo-Danebrock R, Neff F, Royer HD, Eckstein N, Mohrmann S, Ting E, Kiechle M, Poremba C, Nitz U, Harbeck N.

J Clin Oncol. 2009 Dec 20;27(36):6144-51. doi: 10.1200/JCO.2008.19.6261. Epub 2009 Nov 9.

PMID:
19901122
37.

Triple-negative breast cancer--current status and future directions.

Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N.

Ann Oncol. 2009 Dec;20(12):1913-27. doi: 10.1093/annonc/mdp492. Epub 2009 Nov 9. Review.

PMID:
19901010
38.

Adjuvant Chemotherapy of Breast Cancer.

Nitz U, Cardoso F, Gnant M, Thomssen C.

Breast Care (Basel). 2009 Nov;4(5):339-341. doi: 10.1159/000252088. Epub 2009 Oct 21. No abstract available.

39.

Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.

Braun M, Jacobs VR, Wagenpfeil S, Sattler D, Harbeck N, Nitz U, Bernard R, Kuhn W, Ihbe-Heffinger A.

Onkologie. 2009 Sep;32(8-9):473-81. doi: 10.1159/000226211. Epub 2009 Jul 27.

PMID:
19736510
40.

Dose in (adjuvant) chemotherapy of breast cancer.

Nitz U.

Cancer Treat Res. 2009;151:239-53. doi: 10.1007/978-0-387-75115-3_15. Review. No abstract available.

PMID:
19593516
41.

Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer).

Beckmann MW, Blohmer JU, Costa SD, Diedrich K, Diel I, Eiermann W, Friese K, Gerber B, Harbeck N, Hilfrich J, Janni W, Jaenicke F, Jonat W, Kaufmann M, Kiechle M, Koehler U, Kreienberg R, von Minckwitz G, Moebus V, Nitz U, Schneeweiss A, Thomssen C, Wallwiener D.

Breast Care (Basel). 2009;4(2):109-116. Epub 2009 Apr 24.

42.

Nuclear karyopherin alpha2 expression predicts poor survival in patients with advanced breast cancer irrespective of treatment intensity.

Gluz O, Wild P, Meiler R, Diallo-Danebrock R, Ting E, Mohrmann S, Schuett G, Dahl E, Fuchs T, Herr A, Gaumann A, Frick M, Poremba C, Nitz UA, Hartmann A.

Int J Cancer. 2008 Sep 15;123(6):1433-8. doi: 10.1002/ijc.23628.

43.

[Prognostic and predictive impact of protein expression profiling in high risk breast cancer patients treated with high-dose chemotherapy].

Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, Gabbert HE, Nitz U, Poremba C.

Verh Dtsch Ges Pathol. 2007;91:187-96. German.

PMID:
18314614
44.

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial.

Gluz O, Nitz UA, Harbeck N, Ting E, Kates R, Herr A, Lindemann W, Jackisch C, Berdel WE, Kirchner H, Metzner B, Werner F, Schütt G, Frick M, Poremba C, Diallo-Danebrock R, Mohrmann S; West German Study Group.

Ann Oncol. 2008 May;19(5):861-70. doi: 10.1093/annonc/mdm551. Epub 2008 Jan 3.

PMID:
18174609
45.

Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer.

Janni W, von Minckwitz G, Möbus V, Nitz U.

Breast Care (Basel). 2008;3(s1):17-20. Epub 2008 Apr 26. No abstract available.

46.

C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy.

Diallo R, Ting E, Gluz O, Herr A, Schütt G, Geddert H, Mohrmann S, Gabbert HE, Nitz U, Poremba C.

Verh Dtsch Ges Pathol. 2006;90:177-85.

PMID:
17867595
47.

Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy.

Diallo-Danebrock R, Ting E, Gluz O, Herr A, Mohrmann S, Geddert H, Rody A, Schaefer KL, Baldus SE, Hartmann A, Wild PJ, Burson M, Gabbert HE, Nitz U, Poremba C.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):488-97.

48.

Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.

Kröger N, Frick M, Gluz O, Mohrmann S, Metzner B, Jackisch C, Ko Y, Lindemann HW, Meier CR, Lohrmann HP, Ruffert U, Hänel M, Bodenstein H, Neubauer A, Ehninger G, Wolf HH, Kolbe K, Burock K, Zander AR, Nitz U.

J Clin Oncol. 2006 Aug 20;24(24):3919-26.

PMID:
16921043
49.

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO.

J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45.

PMID:
16882940
50.

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.

Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, Werner C, Ziske C, Kirchner H, Metzner B, Souchon R, Ruffert U, Schütt G, Pollmanns A, Schmoll HJ, Middecke C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rösel S, Schwenzer T, Wernet P, Hinke A, Bender HG, Frick M; West German Study Group.

Lancet. 2005 Dec 3;366(9501):1935-44. Erratum in: Lancet. 2006 Mar 4;367(9512):730.

PMID:
16325695

Supplemental Content

Support Center